Member Info for cwebb07

Some list of associated partners Faron are mixing with at the
Cancer IO Sebinar “Next-gen immunotherapies: Innate immunity.
One of the big boys would be next to get into bed with if you know what I mean

Really doesn't seem alot for the potential here

https://twitter.com/Cancer_IO_/status/1393117334596947968?s=19

We need to challenge Markku on
*Are your timescales realistic because you have slipped in the past.
*You have said we are in a SSV period but the SP has fallen.
*When will results be available that will allow partners to be brought on board.
*Are you planning any future fund raise because you dropped one on shareholders right after the last Q&A.
* Are you planning to partner before any future fund raise.

Anyone like to suggest anymore ;-)

I think many companies have failed in the past 15months regarding covid...Faron being one of them...but you are tight Traumakine will still be required for Ards plus the US Dept of Defence slant on trauma injuries so we have plenty to keep the faith on.

I do believe whoever gets to ask a question in the upcoming Q&A aldoe ask Markku direct pointed questions so he can't provide the stock polished answers.

Unless there is news it is stuck here for ever

I did he just laughed and said feck the lot of you

.

Patent protection for Traumakine in the Us

Too many sellers to gain any traction.
Those in at the higher SP levels quite clearly have a different view than those in at sub 10p.
Stuck in this range until final outcome is concluded and don't forget this is AIM and rarely goes in PIs preferred outcome.

Not to listen to the rampers all the time they know as much as the next guy

I agree, keep well away from the US at the moment and let's get positive trial info that will push us past £10.
Then let the partners come crawling begging to get in

Are they inept at selling or they just don't have a product that anyone wants to pay money for?

Should see a decent rise now that Timo dragged the price down with his sneaky order lol

Wow

I see that Maija is also presenting.

12:00 pm Modelling Macrophage Targeting in The TME Using Patient-Derived Tumor Explants
Maija Hollmén
Adjunct Professor, University of Turku
Synopsis
Pre-clinical and clinical development of bexmarilimab
Breast tumor and ovarian ascites samples -what can they tell us about immune switch
Nanostring, scRNA and cytokine multiplexing

very positive updates on Bexmarilimab (clevergn) is not faraway!

Definitely
News coming

Sax is the proactive forum a Q&A like the last time??
If so we should hold Markku to task a bit more with some pointed questions with less wriggle room.

"You said we are in a period of SSV and yet the SP and dropped around a third since the last Q&A.....please explain "

The above is also a fact.
Those say they are comfortable are abviously not telling the truth and must be concerned giving the time this has taken to finalise.
There are plenty of sellers at this level to suggest many many people are not seeing the desired outcome....all those except who have millions of shares desperate for the early retirement ticket.